<DOC>
	<DOCNO>NCT00618319</DOCNO>
	<brief_summary>This study examine effect BIIB021 GIST growth metabolism .</brief_summary>
	<brief_title>An Open-Label , 18FDG-PET Pharmacodynamic Assessment Effect BIIB021 Subjects With Gastrointestinal Stromal Tumors ( GIST )</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Age great equal 18 year time inform consent . Pathologically confirm GIST refractory , intolerant , candidate imatinib sunitinib therapy . FDG PET standard uptake value ( SUVmax ; average maximum 5 lesion ) great equal 2 screening . ECOG performance status less equal 2 . Lab value consistent adequate renal hepatic bone marrow function . Must utilize effective contraception . Prior treatment imatinib , sunitinib , sorafenib 14 day day 1 . Prior treatment Hsp90 inhibitor time . Prior antitumor therapy include prior experimental agent , approve antitumor small molecule ( exclude imatinib , sunitinib , sorafenib ) biologics , radiotherapy 28 day &lt; 3 half life ( whichever longer ) start BIIB021treatment . Diabetes treat insulin and/ concurrent severe uncontrolled medical disease ( i.e , systemic infection , hypertension , coronary artery disease , congestive heart failure ) . History of/ predisposition seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>